IL33 and Alzheimer disease: Itepekimab (REGN3500) is another anti-IL-33 monoclonal antibody which was investigated for the treatment of AD as a monotherapy and in combination with dupilumab, but both trials (NCT03738423, NCT03736967) were terminated due to lack of efficacy.